A Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers.

Inclusion Criteria: * Able to understand the nature of the study, comply with the protocol, and provide informed consent. * Subjects willing to adhere to protocol requirements and to finish the study. * Subjects were willing to use methods of contraception from the time of screen to 6 months post the last dose administration. * Subjects aged between 18 and 55 years (both inclusive). * Subject's weight within normal range according to normal values for Body Mass Index (19.00 to 26.00 kg/m2 (both inclusive)) ,with minimum of 50 kg weight for male, 45 kg weight for famale. * Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable normal range. Exclusion Criteria: * History or presence of significant smoking (more than 5 cigarettes/day prior to 3 months the first dose of the study drug). * Hypersensitivity to different kinds of drugs and food. * Presence of significant alcoholism or drug abuse. * Volunteer who have donated blood or lose blood(\>450mL)within past 90 days prior to the first dose of the study drug. * Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 28 days prior to dosing of the study. * Use of any prescribed medication or OTC medicinal products during the last 14 days prior to dosing of the study. * Consumption of spcial food(including gragon fruit, mango, grapefruits) or strenuous excercise,or other factors which may effect the absorption,distribution,metabolism,excretion of drugs for within 2 weeks prior to dosing of the study. * Any treatment which could bring about induction or inhibition of CYP3A4. * Volunteer who have participation in a drug research study within past 90 days prior to the first dose of the study drug. * Difficulty in swallowing or other gastrointestinal disease or disorder. * Presence of an abnormal electrocardiogram (ECG), which was clinically significant. * Female subjects who were breast-feeding or had a positive pregnancy test at screening or at any time during the study. * Subjects with abnormal health as determined by personal medical history, clinical examination and laboratory examinations,which was clinically significant. * Subjects who, in the opinion of the Investigator, should not participate in the study.